MedTrace Logo

Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain

NCT00488787 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-02-07

No results posted yet for this study

Summary

Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3 hours post administration and assess pain intensity and pain relief throughout the 3 hour postoperative period.

Conditions

  • Pain, Postoperative

Interventions

DRUG

intranasal ketamine

low dose

DRUG

intranasal ketamine

medium dose

DRUG

intranasal ketamine

high dose

DRUG

placebo

placebo

Sponsors & Collaborators

  • Javelin Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Kyle Christensen, DDS · Jean Brown Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-31
Primary Completion
2001-04-30
Completion
2001-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00488787 on ClinicalTrials.gov